

## Peer Review File

Article information: <https://dx.doi.org/10.21037/cco-23-41>

### Reviewer A

The authors write a very good commentary of the article. They have captured all the nuances involved in the study. Very well written.

### Reviewer B

Overall, the present editorial comment highlights the main strengths and weaknesses of the randomized controlled trial performed and published by Li SH et al. With this critical commentary, authors provide an interesting insight into the new pathway opened by the use of HAIC as an adjuvant therapy for HCC patients.

Otherwise, some minor issues have been observed:

Comment 1: HCC is described as the seventh most common cancer worldwide. However, Sung et al. (10.3322/caac.21660) reported that liver cancer is placed as the sixth most common cancer worldwide.

Response 1: We have edited as 6<sup>th</sup> most common cancer.

Comment 2: - Line 25: “oxaliplatin-based” should replace “oxaliplatin based”.

Response 2: We have edited as “oxaliplatin-based”.